Thermo Fisher Scientific (NYSE:TMO) issued an update on its FY 2019 earnings guidance on Wednesday morning. The company provided EPS guidance of $12.28-12.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.25. The company issued revenue guidance of $25.34-25.5 billion, compared to the consensus revenue estimate of $25.43 billion.Thermo Fisher Scientific also updated its FY19 guidance to $12.28-12.34 EPS.
NYSE TMO traded down $3.52 during trading hours on Thursday, reaching $293.41. 48,580 shares of the company’s stock were exchanged, compared to its average volume of 1,615,755. The company has a market capitalization of $112.53 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 1.84 and a beta of 1.13. Thermo Fisher Scientific has a one year low of $208.34 and a one year high of $305.45. The company’s 50-day moving average is $288.56 and its two-hundred day moving average is $281.56. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.49.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, topping the consensus estimate of $2.88 by $0.06. The company had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $2.62 EPS. Research analysts predict that Thermo Fisher Scientific will post 12.25 earnings per share for the current fiscal year.
In other news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the completion of the sale, the chief executive officer now owns 342,193 shares of the company’s stock, valued at approximately $97,466,832.19. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the completion of the sale, the director now directly owns 28,592 shares of the company’s stock, valued at approximately $7,803,614.56. The disclosure for this sale can be found here. In the last three months, insiders sold 54,104 shares of company stock valued at $15,418,539. 0.45% of the stock is currently owned by insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Read More: What is the G-20?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.